Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics

NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036)

INVENTORS

• Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*

SHORT DESCRIPTION
MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders.

BACKGROUND
Leukemia and brain tumors continue to pose significant clinical challenges. Current treatments exhibit modest efficacy and can produce severe side effects, as noted by recent data from the National Cancer Institute. Additionally, conventional therapies for CNS diseases are limited by their poor ability to cross the blood-brain barrier. These shortcomings underscore the need for new, targeted approaches in treating both hematologic and neurological cancers and CNS disorders.

ABSTRACT
Northwestern researchers have developed a series of selective inhibitors that target MNK1 and MNK2 kinases. This approach features a unique pyrimidine core paired with a benzimidazole hinge-binding motif to improve selectivity. A novel ether linker further sharpens MNK1/2 specificity compared to traditional amine linkers. In vitro studies show reduced leukemic cell viability, induced apoptosis, and decreased leukemic progenitor colony formation. Pharmacokinetic analysis in small animal models demonstrates high oral bioavailability, a promising half-life, and exceptional brain penetration. These data suggest that this inhibitor is a strong candidate for treating cancer and CNS disorders.

APPLICATIONS

• Cancer treatment: Focus on reducing cancer cell viability and proliferation in various forms of cancer, including leukemia (AML), breast cancer, and brain cancer.
• CNS disorders: Potential therapy for other neurological disorders, including Alzheimer's Disease.
• Research tool: Enables in vivo studies to explore MNK kinase function in cancer.
• Drug development: Provides a platform for advancing novel, drug-like MNK inhibitors.

ADVANTAGES

• Enhanced selectivity: Offers improved MNK1/2 targeting through a unique ether linkage.
• Promising oral bioavailability: Supports convenient, patient-friendly administration.
• High brain penetration: Overcomes blood-brain barrier challenges for CNS applications.
• Potent anti-leukemic activity: Effectively reduces cell viability and inhibits colony formation.

PUBLICATIONS

• Jonathan B Bell et a.l, MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Mol Cancer Res. October 13, 2016
• Rama K Mishra et al., Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening. Chem Biol Drug Des. July 1, 2019.
• Ann Fernandez et al., Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer. RSC Med Chem. May 9, 2023
• Purav P Vagadia et al., Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia. J Med Chem. March 4, 2025

DEVELOPMENT STAGE
TRL-4 - Prototype Validated in Lab: Key functions have been demonstrated through in vitro experiments confirming the potency and selectivity of the MNK kinase inhibitor, and inhibitor pharmacokinetics and brain penetration have been demonstrated in small animal models.

IP STATUS
Multiple US patents issued (10,093,668, 10,851,082) and pending (19/548,871).